TickerTalks
Browse all tickers →
TickerTalks›$PRAX
PRPRAX

Praxis Precision Medicines, Inc.

$PRAX·$6.9B·Biotechnology·Healthcare
$317.90+3.1%YTD+6.1%1Y+474.7%
Mentions · last 7 days
2026-07-10: 1 posts2026-07-11: 0 posts2026-07-12: 0 posts2026-07-13: 10 posts2026-07-14: 3 posts2026-07-15: 2 posts2026-07-16: 10 posts26+15%
Price updated 12m ago·X counts updated 17h ago
PRPRAX
$PRAXPraxis Precision Medicines, Inc.
$317.90+3.15%26 posts+15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $PRAX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Relutrigine PDUFA deferred to Dec 27; the whole story is that date.

Praxis is a clinical-stage CNS biotech with essentially no revenue and quarterly losses around $3.20-$3.52 EPS, so the fundamentals aren't the point — the calendar is.

  • The FDA pushed the PDUFA decision date for relutrigine (for SCN2A/SCN8A developmental and epileptic encephalopathies, ultra-rare pediatric seizures) out three months to December 27, 2026 to review additional analyses. That's the make-or-break event.
  • A separate collaboration with Remagine Labs to develop a transdermal (skin-patch) formulation of ulixacaltamide for essential tremor adds a second, earlier-stage optionality.
  • Auditor change (dismissed Ernst & Young effective June 29 with no adverse opinions) is worth noting but the 8-K explicitly says the prior opinions were clean.
  • Insider action is mixed: a small share gift by director Marcio Souza plus director Jill DeSimone exercising 23,200 options and selling 11,600 shares for ~$3.6M — an option-exercise sale, not a directional call.

Close: The stock is up ~475% over the last year and near 52-week highs (pos_52w 0.82). Between now and December that's binary risk on one drug approval.

Agrees with X sentimentX frames PRAX as an oversold CNS-basket rebound; the verdict agrees that near-term action is sentiment/positioning rather than earnings but weights the PDUFA extension more heavily.

What to watch: Any interim regulatory correspondence on relutrigine; ulixacaltamide Ph2 tremor readout timing; new auditor engagement; insider Form 4 activity clustering near the PDUFA date.

On the calendar: 2026-12-27 — FDA PDUFA action date for relutrigine NDA (extended from prior date)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-13

Praxis Precision Medicines announced a strategic collaboration with Remagine Labs to develop transdermal ulixacaltamide for essential tremor, including an equity investment in Remagine Labs. PRAX rose 2.8% on a strong day for CNS names alongside XENE (+10.4%), CMPS (+7.5%), and RAPP (+5.8%), with traders framing it as an oversold-name recovery from June panic selling.

Read the AI verdict + X sentiment for $PRAX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops sodium and potassium channel modulators for epilepsy and neurological disorders in clinical trials.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRAX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $PRAX

Neutral — Develops sodium and potassium channel modulators for epilepsy and neurological disorders in clinical trials; this business's revenue is largely decoupled from the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-25.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-3.20$-3.58+10.6%
Q4 2025Feb 19, 2026$-3.50$-3.13-12.0%
Q3 2025Nov 5, 2025$-3.36$-3.45+2.6%
Q2 2025Aug 4, 2025$-3.31$-3.40+2.6%
Next earningsMon, Aug 3·consensus EPS $-3.67

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-3.20$-86.1M
Q4 FY25$0-100.0%——$-3.52$-77.3M
Q3 FY25$0-100.0%——$-3.36$-64.7M
Q2 FY25$0-100.0%——$-3.31$-54.8M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$3.5M$1.6M – $5.1M-$15.21-$16.44 – -$14.0013
FY27$344.7M$172.6M – $444.2M-$10.22-$19.84 – -$4.6813
FY28$1.1B$1.1B – $1.1B$7.23-$12.17 – $31.2816
FY29$2.2B$984.7M – $3.6B$29.54$8.39 – $54.6215
FY30$3.5B$1.6B – $5.7B$52.30$14.85 – $96.6915

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.82%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+14.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 23.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.765-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 24Jill DesimoneDirector11.6K sh$3.6M
+ 17 other (15 awards · 1 gift · 1 exempt) in window

See when $PRAX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial eventJul 28-K — Item 4.01
AI summary

Praxis Precision Medicines dismissed Ernst and Young as independent auditor effective June 29, 2026; EY's clean opinions for FY2024 and FY2025 contained no adverse opinions, qualifications, or disagreements. No replacement auditor was named in the filing. Notable auditor change requiring investor attention; clean prior track record reduces immediate concern.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Praxis Precision Medicines held its 2026 Annual Meeting on June 10, 2026. Shareholders elected three Class III director nominees — Gregory Norden, Marcio Souza, and William Young — each to serve through 2029; ratified Ernst & Young LLP as independent auditor; and approved the advisory say-on-pay vote on executive compensation. Routine annual governance with no material business changes or contested outcomes.

8-KPress release / Reg FDMay 78-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PRAX reported period ending 2026-05-13 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

8-K/AOfficer or director change (amended)Feb 108-K/A — Item 5.02: Officer or director change
+ 23 other (11 13Gs · 6 routine 8-Ks · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremorglobenewswire.com·10d agoPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·15d agoPraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathiesglobenewswire.com·18d agoPraxis' Seizure Drug Move Towards Faster Development After Positive Trial Resultsbenzinga.com·25d agoPraxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variantsglobenewswire.com·25d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · last 7 days

No standout posts about $PRAX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport